DCGI approves psoriasis injection for 'restricted emergency use' to treat COVID-19 patients
Drugs Controller General of India approved monoclonal antibody injection Itolizumab for limited use to treat moderate to severe cases of COVID-19.
New Delhi: India's drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, officials told PTI on Friday.
Considering the unmet medical needs to treat COVID-19 , Drugs Controller General of India, Dr VG Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of 'cytokine' release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19 , they said.
"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome," an official told PTI.
"It is already an approved drug of Biocon for treating psoriasis for last many years," the official said.
Written informed consent of each patient is required before the use of this drug, he said.
As European football clubs struggle to make up for revenue lost in the pandemic, one untapped source of revenue is stadium naming rights, but exploiting them may not be straightforward.
'You are looting people': Kerala HC slams private hospitals, lauds LDF govt's price cap on COVID-19 treatment
The Pinarayi Vijayan government has capped the price of the general ward at Rs 2,500, which includes nursing, boarding, blood transfusion, and oxygen services
India must impose lockdown for few weeks to break chain of COVID-19 transmission, says Anthony Fauci
Top US public health expert also recommended taking the help of the armed forces to immediately build makeshift field hospitals